Cancer mortality according to lipid-lowering drugs and lipoproteins in a general population

Current Medical Research and Opinion

Volumn 27, Issue 10, 2011, Pages 1963-1971

  Berard E ^a   Bongard, V ^a   Dallongeville, J ^b   Arveiler, D ^c   Ruidavets, J B ^a   Ferrires J ^a,d  

^a Faculté de Médecine Centre Hospitalo universitaire   (France)

^b UNIV LILLE   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Cancer mortality; HDL cholesterol; Lipid lowering drugs; Non HDL cholesterol; Plasma lipoproteins; Risk factors

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN;

ADULT; ARTICLE; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR RISK; CAUSE OF DEATH; CIGARETTE SMOKING; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; FRANCE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEALTH SURVEY; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME;

ADULT; CHOLESTEROL; DYSLIPIDEMIAS; FEMALE; FRANCE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 80053011267     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.616191     Document Type: Article

References (32)

1. Saha SA, Kizhakepunnur LG, Bahekar A, et al. The role of fibrates in the prevention of cardiovascular disease. A pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007;154:943-53 (Pubitemid 350001283)
2. Dale KM, Coleman CI, Henyan NN, et al. Statins and cancer risk: a metaanalysis. JAMA 2006;295:74-80
3. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and meta-analysis. Int J Cancer 2007;120:833-43 (Pubitemid 46175404)
4. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: metaanalysis of randomised controlled trials. BMJ 2009;338:b2376
5. WHO. The global burden of disease: 2004 update. Available at: http://www.who.int/healthinfo/global-burden-disease/GBD-report-2004update-full. pdf [Last accessed 10 July 2010]
6. Law MR, Thompson SG. Low serum cholesterol and the risk of cancer: an analysis of the published prospective studies. Cancer Causes Control 1991; 2:253-61
7. Jacobs D, Blackburn H, Higgins M, et al. Report of the Conference on Low Blood Cholesterol: mortality associations. Circulation 1992;86:1046-60
8. Eichholzer M, Stähelin HB, Gutzwiller F, et al. Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study 1-3. Am J Clin Nutr 2000;71:569-74
9. Gardette V, Bongard V, Dallongeville J, et al. Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort). Am J Cardiol 2009;103:381-6
10. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000;355:675-87 (Pubitemid 30107623)
11. Marques-Vidal P, Ruidavets JB, Amouyel P, et al. Change in cardiovascular risk factors in France, 1985-1997. Eur J Epidemiol 2004;19:25-32 (Pubitemid 38250050)
12. INSERM-IFR69. Mise en oeuvre du dé cret n-98-37 autorisant l'accè s aux donné es relatives au dé cè s des personnes inscrites au Ré pertoire National d'Identification des Personnes Physiques (RNIPP) dans le cadre des recherches dans le domaine de la santé . Available at: http://ifr69.vjf.inserm. fr/svcd.html [Last accessed 10 July 2010]
13. Friedewald WT, Levy RI, Fredrickson DS, et al. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1978;18:499-502
14. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509
15. Aouba A, Pé quignot F, Le Toullec A, et al. Les causes mé dicales de dé cès en France en 2004 et leur é volution 1980-2004. Bull Epidemiol Hebdo 2007; 35-36:308-14
16. Danaei G, Vander Hoorn S, Lopez AD, et al. Comparative Risk Assessment Collaborating Group (Cancers). Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet 2005;366:1784-93 (Pubitemid 41642642)
17. Lemmens P, Tan ES, Knibbe RA, et al. Measuring quantity and frequency of drinking in a general population survey: a comparison of five indices. J Stud Alcohol 1992;53:476-86
18. Conigrave KM, Davies P, Haber P, et al. Traditional markers of excessive alcohol use. Addiction 2003;98(Suppl 2):31-43 (Pubitemid 38030760)
19. Fiorenza AM, Branchi A, Sommariva D, et al. Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects. Int J Clin Lab Res 2000;30:141-5 (Pubitemid 32151973)
20. Muntoni S, Atzori L, Mereu R, et al. Serum lipoproteins and cancer. Nutr Metab Cardiovasc Dis 2009;19:218-25
21. Kucharska-Newton AM, Rosamond WD, Schroeder JC, et al. HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study. Lung Cancer 2008;61:292-300
22. Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 2010;55:2846-54
23. Von Eckardstein A, Hersberger M, Rohrer L, et al. Current understanding of the metabolism and biological actions of HDL. Curr Opin Clin Nutr Metab Care 2005;8:147-52 (Pubitemid 40289474)
24. Alawi A, Alsheikh-Ali, Thomas A, et al. Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 2008;52:1141-7
25. Gränsbo K, Melander O, Wallentin L, et al. Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol 2010;55:1362-9
26. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010;340:c2197
27. Sleijfer S, van der Gaast A, Planting AS, et al. The potential of statins as part of anti-cancer treatment. Eur J Cancer 2005;41:516-22 (Pubitemid 40292731)
28. Dormuth CR, Patrick AR, Shrank WH, et al. Statin adherence and risk of accidents: a cautionary tale. Circulation 2009;119:2051-7
29. Ford I, Murray H, Packard CJ, et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-86 (Pubitemid 47572633)
30. Tenkanen L, Manttari M, Kovanen PT, et al. Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 2006;166:743-78
31. Strandberg TE, Pyorala K, Cook TJ, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004;364:771-7 (Pubitemid 39165096)
32. Ruidavets JB, Bataille V, Dallongeville J, et al. Alcohol intake and diet in France, the prominent role of lifestyle. Eur Heart J 2004;25:1153-62 (Pubitemid 38834073)